Cellectis’ Post

Exciting news! Results from 3 independent preclinical efficacy studies reveal the potential of IHP-102 as the first on-demand therapeutic for treating vaso-occlusive episodes in sickle cell disease patients. These significant findings will be presented at ASH on Dec 8: https://lnkd.in/gTJREB8U https://lnkd.in/gY4SXd-x https://lnkd.in/gvUf37hN A special thank you to the committed and innovative IHP team, along with our forward-thinking partners at Emory University, Versiti Blood Research Institute, and BioChip Labs. Together, we are pioneering home-based acute intervention in sickle cell disease care. #SCD

Great to see this new data posted as a preprint on medRxiv about our lead program, LTI-03 for idiopathic pulmonary fibrosis (#IPF). In this randomized dose-escalation study, inhaled LTI-03 was generally well tolerated, reduced multiple fibrosis-associated biomarkers, and helped preserve key lung cells needed for repair. It’s a differentiated effect not typically seen with current IPF therapies. These findings build on our prior data and support our ongoing global Phase 2 RENEW trial, now moving forward in the U.S., U.K., Germany, Poland, and Australia. For patients who continue to face limited options and progressive lung loss, we believe LTI-03 may represent a meaningful step forward. 🔗 Link to press release in comments #PulmonaryFibrosis #Fibrosis

Artiva Biotherapeutics reported third quarter 2025 results and recent business highlights. Artiva will host a virtual event today at 8 a.m. ET to discuss initial safety and translational data from AlloNK® in combination with anti-CD20 monoclonal antibodies across autoimmune diseases, including outpatient feasibility and tolerability observations. See the release for more details: https://lnkd.in/grecs4s2 #ARTV #AlloNK #NKcell #NKcells #NKcelltherapy #autoimmunedisease

Blood tests for liver disease and GLP-1s' potential to treat early stage liver disease are two major themes of this year's American Association for the Study of Liver Diseases (AASLD) conference, says Resolution Therapeutics' Lara Campana. Watch:

Resolution Therapeutics cofounder, SVP of Research and Translational Science, and #macrophage scientist extraordinaire 👩🔬 Dr. Lara Campana, distils this year's AASLD key takeaways. 🚨 Spoiler altert 🚨: it's how about far GLP-1s and non-invasive tests have come and what that means for the field. 📹 Watch here:

Novartis has announced positive results from two Phase 3 studies, NEPTUNUS-1 and NEPTUNUS-2, evaluating its investigational therapy Ianalumab in adults with active Sjögren’s disease. Both trials met their primary endpoints, showing significant improvement in disease activity compared with placebo. Sjögren’s disease is a chronic autoimmune condition with limited treatment options, and there are currently no approved targeted systemic therapies. Ianalumab, which works through dual B-cell depletion and BAFF-R inhibition, represents a promising approach to address this unmet need. These findings bring renewed optimism for patients and researchers in the autoimmune field, signaling meaningful progress toward more personalized and effective treatments. #Novartis #SjögrensDisease #ClinicalTrials #AutoimmuneDisease #HealthcareResearch

🚀Bioatla Showcases CAB Technology at ESMO TAT ASIA BioAtla demonstrated the promise of its Conditionally Active Biologics™ (CAB) platform at ESMO TAT ASIA, advancing the fight against refractory metastatic cancer. The company highlighted preliminary results from the First-in-Human Phase 1 Study of BA3182, a novel therapeutic designed for precision oncology. Key Takeaways: Precision Design: BA3182 is a Dual CAB EpCAM x CD3 Bispecific T-cell Engager (TCE). This innovative design aims to activate T-cells only in the tumor microenvironment, significantly reducing systemic toxicity. High-Need Patients: The study focused on patients with Treatment Refractory Metastatic Adenocarcinoma, addressing a critical unmet medical need. Impact: CAB technology is poised to redefine cancer therapy by offering tumor-selective activation and potentially improving the therapeutic window for T-cell engagers. #Oncology #ImmunoOncology #Biotech #ESMOTAT #CancerResearch #CABTechnology #ClinicalTrials

We’ll be at American College of Rheumatology Convergence 2025 to present follow-up data from our Phase 1 study of SPY072, our potential first- and best-in-class anti-TL1A agent in development for rheumatic diseases, as well as new preclinical data that reinforce the role of TL1A as a key driver of inflammation in #arthritis. These findings further validate our approach and support the rationale for our SKYWAY Phase 2 basket study evaluating SPY072 in #rheumatoidarthritis, #psoriaticarthritis, and #axialspondyloarthritis.    Posters will be presented during the #ACR25 Congress. Details below and review our forward-looking statement legend at https://lnkd.in/eXYwBz3v

ICYMI: we presented preclinical data at #AHA20205 demonstrating that degrading NEK7 to modulate the NLRP3 inflammasome represents a novel and differentiated approach with potential therapeutic application in multiple cardiovascular and cardiometabolic diseases.   CSO Sharon Townson comments on the significance of these findings.   Learn more: https://bit.ly/3LzhSlM

Autoimmune diseases affect far more than the body, they shape daily life. Having spent much of my career in Immunology, I’ve seen the impact first-hand and spoken with many patients who've shared their frustrations and hopes. At Novartis, we’re proud to push boundaries where progress has stalled, with a leading pipeline and a deep commitment to patient-driven care. At ACR Convergence 2025, we’re sharing new data on Sjögren’s disease, still underserved despite being the second most common rheumatic condition. Our Spotlight on Sjögren’s study shows 94% of patients are unsatisfied with current therapies. Hear from Ana Vieira, VP of Sjögren Europe, whose story reminds us why human-centered innovation truly matters. #ACR25 #Sjögren #ReimagineMedicine #Novartis